Noa Therapeutics secures pre-seed financing to transform the treatment of inflammatory disease
Noa Therapeutics secures oversubscribed pre-seed financing for novel therapies addressing inflammatory diseases, led by diverse investors and board.
Noa Therapeutics secures oversubscribed pre-seed financing for novel therapies addressing inflammatory diseases, led by diverse investors and board.
Discover how Synmedix is combating antibiotic resistance with support from the SOPHIE program and Synapse Life Science Competition.
Allarta Life Science, a regenerative medicine company using novel hydrogels to enable cell-based therapies for type 1 diabetes (T1D), has
LCTG-001 on course to be the first FDA-approved biologic from human milk for pediatric patients with Common Variable Immunodeficiency.
Through the SOPHIE program, PreOperative Performance will enter a 12-month co-development partnership with The Research Institute of St. Joe’s Hamilton
This press release was originally published by OBIO on April 11, 2023. Read the original post here. (Windsor, ON) –
Allarta Life Science leverages the SOPHIE program with the goal of licensing technology and commercializing treatments.Â
Innovation Factory Client, Rapid Dose Therapeutics is a Canadian life sciences company which provides disruptive proprietary drug delivery technologies designed to
EMN, a Canadian medical nutrition company, has raised a $1.2 Million seed round led by several prominent angel investors from
Noa Therapeutics secures oversubscribed pre-seed financing for novel therapies addressing inflammatory diseases, led by diverse investors and board.
Discover how Synmedix is combating antibiotic resistance with support from the SOPHIE program and Synapse Life Science Competition.
Allarta Life Science, a regenerative medicine company using novel hydrogels to enable cell-based therapies for type 1 diabetes (T1D), has received an award from JDRF, the leading global T1D research and advocacy organization.
LCTG-001 on course to be the first FDA-approved biologic from human milk for pediatric patients with Common Variable Immunodeficiency.
Through the SOPHIE program, PreOperative Performance will enter a 12-month co-development partnership with The Research Institute of St. Joe’s Hamilton
This press release was originally published by OBIO on April 11, 2023. Read the original post here. (Windsor, ON) –
Allarta Life Science leverages the SOPHIE program with the goal of licensing technology and commercializing treatments.Â
Innovation Factory Client, Rapid Dose Therapeutics is a Canadian life sciences company which provides disruptive proprietary drug delivery technologies designed to
EMN, a Canadian medical nutrition company, has raised a $1.2 Million seed round led by several prominent angel investors from
Get the latest updates delivered straight to your inbox! Stay notified about companies on the grow, the latest tech trends, funding news and opportunities, industry insights, upcoming events and more from across Hamilton and Halton’s innovation ecosystem.
Network with 250+ industry professionals, discover emerging solutions from our innovators, and celebrate entrepreneurship within the Hamilton-Halton ecosystem.